2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: Established knowledge and evidence gaps

Diabetes and Vascular Disease Research

Volumn 11, Issue 1, 2014, Pages 5-10

  Paneni, Francesco ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EVOLOCUMAB; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PACLITAXEL; RAPAMYCIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG ELUTING STENT; EVIDENCE BASED PRACTICE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION;

CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; EARLY DIAGNOSIS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; INDIVIDUALIZED MEDICINE; PRACTICE GUIDELINES AS TOPIC; PREDIABETIC STATE; RISK FACTORS;

EID: 84890453991     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164113512859     Document Type: Note

References (20)

1. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report no. 99.2, 1999. Geneva: World Health Organization, http://whqlibdoc.Who.Int/hq/1999/who-ncd-ncs-99.2.Pdf
2. International Diabetes Federation. Global burden: prevalence and projections, 2011 and 2030, http://www.Diabetesatlas.Org/content/diabetes-and- impairedglucose-tolerance (2011).
3. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998 ; 339: 229-234
4. Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J. 2011 ; 161: 210-219.e1
5. Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013 ; 34: 2436-2443
6. Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events. A meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999 ; 22: 233-240
7. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 ; 28: 88-136
8. Ryden L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. :
9. Mellbin LG, Anselmino M, Ryden L. Diabetes, prediabetes and cardiovascular risk. Eur J Cardiov Prev R. 2010 ; 17: S9 - S14
10. Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe: the Euro Heart Survey on Diabetes and the Heart. Eur Heart J. 2004 ; 25: 1880-1890
11. Anand DV, Lim E, Hopkins D, et al. Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy. Eur Heart J. 2006 ; 27: 713-721
12. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006 ; 166: 1368-1373
13. Turnbull FM, Abraira C, Anderson RJ, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 ; 52: 2288-2298
14. Gerstein HC, Bosch J, Dagenais GR, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 ; 367: 319-328
15. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol. 2013 ; 12: 130
16. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 ; 358: 580-591
17. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2010 ; 121: 110-122
18. Urban D, Poss J, Bohm M, et al. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013 ; 62: 1401-1408
19. Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009 ; 373: 1190-1197
20. Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 ; 367: 2375-2384